Rapid and Flexible Platform To Assess Anti-SARS-CoV-2 Antibody Neutralization and Spike Protein-Specific Antivirals
Year: 2021
Type: article
Abstract: Assays for rapid biosafety level 2 (BSL2) evaluation of neutralizing properties of antibodies acquired via natural infection or through vaccination is urgently needed. Here, we propose a combinatorial approach in which sera are screened for SARS-CoV-2 spike protein (S) binding using a cell-based immunofluorescent (CBI) assay, and positive samples are further evaluated in a pseudotyped viral multicycle infection-mimicking protocol under BSL2 conditions.
Source: mSphere
Authors: Debora Stelitano, Stuart P. Weisberg, Monica P. Goldklang, Yun Zhu, Francesca T. Bovier, Gavreel F. Kalantarov, Giuseppe Greco, Didier Decimo, Gianluigi Franci, Michele Cennamo, Giuseppe Portella, Massimiliano Galdiero, Cyrille Mathieu, Branka Horvat, Ilya N. Trakht, Anne Moscona, Michael A. Whitt, Matteo Porotto
Institutions: University of Campania "Luigi Vanvitelli", Columbia University, Capital Medical University, Beijing Children’s Hospital, Lyon 1 Université, École Normale Supérieure de Lyon, Centre National de la Recherche Scientifique, Inserm, Centre International de Recherche en Infectiologie, University of Salerno, University of Naples Federico II, University of Tennessee Health Science Center
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,500
Funders: Agence Nationale de la Recherche, Agence Nationale de Recherches sur le Sida et les Hépatites Virales, Fondation de France, National Institutes of Health, Irving Medical Center, Columbia University, National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Disorders and Stroke
Awards: G1280105601, G1297467294, Self-assembling nanoparticles for intranasal delivery of influenza fusion inhibitors, G1973643230, G2032786069, G2100353928, G2614584172, Small molecules to block measles spreading in the central nervous system, Development of therapeutic fusion inhibitor peptides for Measles encephalitis, G5296751580, Self-assembling nanoparticles for intranasal delivery of influenza fusion inhibitors, G6237850065, Development of novel endosome-targeted Ebola virus entry inhibitors as antiviral agents, G7163014271, Tissue Resident Immune Cells in Human Pancreas., G7563060476, G8570300575, G9000055396
OpenAlex ID: W3186551981
